New cholesterol pill shows promise in lowering 'Bad' LDL levels

NCT ID NCT06173570

Completed Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Nov 17, 2025 · Last updated May 16, 2026 · Updated 24 times

Summary

This study tested a new daily medication called AZD0780 in 428 adults with high cholesterol. Participants took either a low or high dose of the drug or a placebo for 12 weeks. The main goal was to see how much the drug lowered 'bad' LDL cholesterol compared to the placebo. The study also checked safety and how the drug affected other blood fats.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site

Huntsville, Alabama, 35801, United States
Research Site

Lincoln, California, 95648, United States
Research Site

Palm Springs, California, 92262, United States
Research Site

Santa Ana, California, 92704, United States
Research Site

Boca Raton, Florida, 33434, United States
Research Site

Hialeah, Florida, 33012, United States
Research Site

Inverness, Florida, 34452, United States
Research Site

Jacksonville, Florida, 32216, United States
Research Site

Indianapolis, Indiana, 46260, United States
Research Site

Louisville, Kentucky, 40213, United States
Research Site

New Windsor, New York, 12553, United States
Research Site

Greensboro, North Carolina, 27408, United States
Research Site

Fargo, North Dakota, 58104, United States
Research Site

San Marcos, Texas, 78666, United States
Research Site

Barrie, Ontario, L4N 7L3, Canada
Research Site

Brampton, Ontario, L6S 0C6, Canada
Research Site

Cambridge, Ontario, N1R 6V6, Canada
Research Site

Concord, Ontario, L4K 4M2, Canada
Research Site

Guelph, Ontario, N1H 1B1, Canada
Research Site

Toronto, Ontario, M6G 1M2, Canada
Research Site

Benešov, 256 01, Czechia
Research Site

Brandýs nad Labem, 250 01, Czechia
Research Site

Brno, 603 00, Czechia
Research Site

Louny, 440 01, Czechia
Research Site

Náchod, 547 01, Czechia
Research Site

Prague, 150 00, Czechia
Research Site

Příbram, 261 01, Czechia
Research Site

Teplice, 415 01, Czechia
Research Site

Uherské Hradiště, 68601, Czechia
Research Site

Aarhus, 8200, Denmark
Research Site

Herning, 7400, Denmark
Research Site

Hvidovre, 2650, Denmark
Research Site

Svendborg, 5700, Denmark
Research Site

Viborg, 8800, Denmark
Research Site

Budapest, 1027, Hungary
Research Site

Debrecen, 4032, Hungary
Research Site

Orosháza, 5900, Hungary
Research Site

Pécs, 7624, Hungary
Research Site

Chūōku, 103-0027, Japan
Research Site

Itabashi-ku, 173-0004, Japan
Research Site

Bratislava, 831 03, Slovakia
Research Site

Brezno, 977 01, Slovakia
Research Site

Lučenec, 984 01, Slovakia
Research Site

Prešov, 080 01, Slovakia
Research Site

Rožňava, 048 01, Slovakia
Research Site

Svidník, 08901, Slovakia
Research Site

Trebišov, 075 01, Slovakia
Research Site

A Coruña, 15006, Spain
Research Site

Barcelona, 08041, Spain
Research Site

Córdoba, 14004, Spain
Research Site

Ferrol, 15405, Spain
Research Site

Santiago(A Coruña), 15706, Spain
Research Site

Seville, 41004, Spain
Research Site

Seville, 41013, Spain
Research Site

Seville, 41071, Spain

Conditions

Explore the condition pages connected to this study.

DYSLIPIDEMIA